Factors associated with spontaneous stone passage in a contemporary cohort of patients presenting with acute ureteric colic: results from the Multi-centre cohort study evaluating the role of Inflammatory Markers In patients presenting with acute ureteric Colic (MIMIC) study

Taimur T. Shah*,[†,‡,§], Chuanyu Gao*, Max Peters[¶], Todd Manning**,
Sophia Cashman*, Arjun Nambiar*, Marcus Cumberbatch*,[††], Ben Lamb*,
Anthony Peacock[‡‡], Marieke J. Van Son[¶], Peter S. N. van Rossum[¶], Robert Pickard[§§],
Paul Erotocritou[¶¶], Daron Smith***, Veeru Kasivisvanathan*,[‡] and British Urology
Researchers in Surgical Training (BURST) Collaborative MIMIC Study Group[1]

*British Urology Researchers in Surgical Training (BURST), London, UK, [†]Division of Surgery and Cancer, Imperial College London, [‡]Division of Surgery and Interventional Science, University College London, [§]Charing Cross Hospital, Imperial Health NHS Trust, London, UK, [¶]Department of Radiation Oncology, Cancer Center, University Medical Center Utrecht, Utrecht, The Netherlands, **Australian Young Urology Researchers Organisation (YURO), Heidelberg, Victoria, Australia, [††]Academic Urology Unit, University of Sheffield, Sheffield, [‡‡]Information Services Division, University College London (UCL), London, [§§]Department of Urology, Newcastle University, Newcastle, UK, [¶¶]Department of Urology, Whittington Hospital, and ***Department of Urology, UCL Hospital, London, UK

[1]PubMed Indexed Collaborators (BURST Collaborative MIMIC Study Group) are presented in Appendix 1.
[Correction added on 18 July 2019, after first online publication: Some author names have been updated in this version.]

Objectives

To assess the relationship of white blood cell count (WBC) and other routinely collected inflammatory and clinical markers including stone size, stone position, and medical expulsive therapy use (MET), with spontaneous stone passage (SSP) in a large contemporary cohort of patients with acute ureteric colic, as there are conflicting data on the role of WBC and other inflammatory markers in SSP in patients with acute ureteric colic.

Patients and methods

Multicentre retrospective cohort study coordinated by the British Urology Researchers in Surgical Training (BURST) Research Collaborative at 71 secondary care hospitals across four countries (UK, Republic of Ireland, Australia, and New Zealand). In all, 4170 patients presented with acute ureteric colic and a computed tomography confirmed single ureteric stone. Our primary outcome measure was SSP, as defined by the absence of need for intervention to assist stone passage (SP). Multivariable mixed effects logistic regression was used to explore the relationship between key patient factors and SSP.

Results

In all, 2518 patients were discharged with conservative management and had further follow-up with a SSP rate of 74% ($n = 1874/2518$). Sepsis after discharge with conservative management was reported in 0.6% ($n = 16/2518$). On multivariable analysis neither WBC, neutrophils count, nor C-reactive protein (CRP) predicted SSP, with an adjusted odds ratio (OR) of 0.97 (95% confidence interval [CI] 0.91–1.04, $P = 0.38$), 1.06 (95% CI 0.99–1.13, $P = 0.1$) and 1.00 (95% CI 0.99–1.00, $P = 0.17$), respectively. MET also did not predict SSP (adjusted OR 1.11, 95% CI 0.76–1.61). However, stone size and stone position were significant predictors. SSP for stones <5 mm was 89% (95% CI 87–90) compared to 49% (95% CI 44–53) for stones ≥5–7 mm, and 29% (95% CI 23–36) for stones >7 mm. For stones in the upper ureter the SSP rate was 52% (95% CI 48–56), middle ureter was 70% (95% CI 64–76), and lower ureter was 83% (95% CI 81–85).

Conclusion

In contrast to the previously published literature, we found that in patients with acute ureteric colic who are discharged with initial conservative management neither WBC, neutrophil count, nor CRP, helps determine the likelihood of SSP. We also found no overall benefit from the use of MET. Stone size and position are important predictors and our present findings represent the most comprehensive SP rates for each millimetre increase in

stone size from a large contemporary cohort adjusting for key potential confounders. We anticipate that these data will aid clinicians managing patients with acute ureteric colic and help guide management decisions and the need for intervention.

Keywords

urolithiasis, spontaneous stone passage, medically expulsive therapy, white blood cell, CRP, inflammatory markers, #UroStone, #EndoUrology

Introduction

Urolithiasis is a very common problem, with a lifetime incidence of up to 19% in men and 8% in women. Recent evidence shows that in high-income countries the incidence is 58.4–1116 per 100 000 people, with incidence increasing over time, and 25% experiencing recurrence [1–4]. In patients who have uncontrollable pain, sepsis or renal impairment, immediate intervention is often necessary. In patients presenting with acute ureteric colic who are clinically stable without an indication for immediate intervention there is uncertainty as to the likelihood of the patient requiring active treatment for their stone. Randomised control trials (RCTs) assessing the use of medical expulsive therapy (MET) to improve spontaneous stone passage (SSP) confirm that three-quarters of stones will pass without the need for any surgical intervention [5–7]. Allowing a stone to pass spontaneously avoids the need for intervention and its associated complications. Once an intervention is carried out, this can often lead to a number of surgical procedures before the patient is stone and stent free, causing burden to patients and healthcare systems [8]. Conversely, managing a stone conservatively that may not pass can lead to re-admission due to pain, infection or a delay in definitive management, so intervention in some patients is important [6].

Key clinical parameters that may influence SSP include stone size, stone position, and the use of MET [5,9,10], although the influence of these factors on SSP has rarely been considered together in a contemporaneous study. A biomarker that could predict which patients will pass their stone spontaneously and which would likely require intervention would be useful in guiding patient management in those who are clinically stable at presentation. A biomarker that is routinely assessed, cheap and widely available to urological centres managing patients with renal colic would be the ideal candidate. White blood cell count (WBC), neutrophil count, and C-reactive protein (CRP) are blood tests that are routinely performed in patients on admission with acute ureteric colic and have attracted attention for their potential as such biomarkers. Previously Sfoungaristos et al. [11] assessed 156 patients and found an increased chance of SSP in patients with a raised WBC or neutrophil count. Conversely, Park et al. [12] assessed 187 patients and showed that the SP rate was 11.4% more frequent in those with a normal neutrophil count when compared to those with a raised count, defined as >74% of the total WBC. Others have

also shown that a raised WBC or CRP was associated with decreased SSP and an increased need for intervention [13,14].

A proposed hypothesis for the observed association was that a stone that passes along the full ureter has an opportunity to cause ureteric wall inflammation and sub-mucosal oedema [11,15], thus generating an inflammatory response resulting in higher inflammatory markers.

However, the conflicting nature of the evidence within the literature and the observation that conclusions on whether this inflammatory response might be improving or reducing the likelihood of SSP were based on studies with very small sample sizes, without power to adjust for key confounding variables. This led to the development of the Multi-centre cohort study evaluating the role of Inflammatory Markers In patient's presenting with acute ureteric Colic (MIMIC) [12–14,16].

Our aim was to establish the association of primarily WBC but also neutrophil count, CRP, and other routinely measured clinical parameters with SSP in an appropriately powered sample, adjusting for key confounders. Specific clinical parameters that we aimed to investigate included stone size, stone position, and MET. Particularly for the role of MET, there is controversy on whether it aids SSP, with the publication of conflicting data between a high-quality RCT, Spontaneous Urinary Stone Passage Enabled by Drugs (SUSPEND), and a robustly performed meta-analysis [5,7].

Patients and methods
Study design

We carried out a multicentre retrospective cohort study according to the principles of the trainee-led collaborative research model [17,18], coordinated by the British Urology Researchers in Surgical Training (BURST) research collaborative. We carried out the study in secondary care hospitals in the UK, Ireland, Australia, and New Zealand. A secondary care hospital was any institution with an accident and emergency department that accepts patients with ureteric colic. We report results according to the STrengthening the Reporting of OBservational studies in Epidemiology (STROBE) guidelines [19] (Appendix S1).

Inclusion criteria included patients presenting with acute ureteric colic who had a solitary ureteric stone diagnosed by non-contrast CT [15]. Exclusion criteria included: patients presenting with non-obstructing renal stones, patients with more than one

ureteric stone, and patients who had a second or subsequent presentation of a previously identified ureteric stone [20]. The primary analysis excluded patients admitted for immediate emergency intervention, e.g., due to sepsis, renal failure, or unmanageable pain. We mitigated for selection bias by including consecutive patients meeting the eligibility criteria identified from each participating institution. Each centre collected data on a minimum of 50 consecutive patients with a minimum of 6 months of follow-up from initial presentation.

We assessed emergency department records, follow-up records, imaging results, and surgical operation notes. We followed-up patients' records until SSP or the patient underwent intervention and in the absence of these events, for a minimum of 6 months. We defined follow-up data as a patient attendance to an outpatient clinic, telephone consultation, an imaging test, or admission to hospital.

Within Australia and New Zealand formal ethical review board approval was granted. In the UK, as per UK NHS Health Research Authority and National Research Ethics Service guidance, ethical exemption applied, and local research and development or clinical audit department approval was granted at each participating site. In the Republic of Ireland, local audit department approval was granted at each participating site. The full study protocol has been published previously [20].

Variables

WBC was the primary determinant of interest. Secondary variables included: neutrophil count, CRP, stone size and stone position, MET, creatinine, hydronephrosis, hydroureter, perinephric stranding, NSAID use, and antibiotic use. Variables were selected a priori on the basis of putative association with SSP based on the literature and on the basis of being routinely available in clinical practice.

The primary outcome was the occurrence of SSP during follow-up. As with other landmark studies in acute ureteric colic, we defined SSP as the absence of the need for intervention to assist stone passage SP [7,21]. This definition allowed either a clinical or radiological confirmation of SP. Due to the real-world nature of the data collection, this pragmatic definition minimised selection bias that would be created by analysing only those patients who had follow-up imaging. The follow-up and need for intervention were determined by local practice and clinical discretion.

For stone position, we classified upper ureteric stones as stones from the renal pelvis to the top of the sacrum, middle ureteric stones as being from the top to the bottom of the sacrum, and lower ureteric stones were classified as stones below the sacrum to the vesico-ureteric junction. The local radiologist determined stone size, the presence of hydronephrosis, hydroureter, and perinephric stranding.

We checked all data for the variables of interest and primary outcome for inconsistencies and outliers, and in addition an independent central quality control team checked the full data records for sense and consistency in 10% of patients chosen at random from each site. We removed one site, due to poor-quality data, who had submitted data on 10 patients.

Statistical analysis

We powered the study as per the accepted minimum criteria of 10 events per variable (EPV) for logistic regression analyses [22]. With 18 variables and assuming a 75% SSP rate, the minimum sample size required was 720 patients [20,22,23]. We added interaction terms between MET and stone size and stone position based on prior clinical evidence [5].

We used univariable logistic regression to determine the association between variables of interest and SSP. Subsequently, a multivariable logistic regression model was constructed, where the outcome of interest was SSP, using data from patients who did not undergo intervention at presentation. We used a random effect to account for clustering of patients within hospitals. The multivariable model included adjustments for gender and age as control variables. We report odds ratios (ORs), related to the probability of SSP for each variable. We treated stone size as a categorical variable with clinically important boundaries derived from the literature [6]. Analyses were performed with multiple imputation by chained equations to determine the effect, if any, from missing data. Data were assumed to be missing at random. Predictive mean matching was used for continuous data, logistic regression for binary variables, and polytomous logistic regression for unordered categorical variables.

Statistical analyses were performed using R version 3.4.4 (R Core Team [2017]. R: A language and environment for statistical computing. R Foundation for Statistical Computing. Vienna. Austria. URL https//www.R-project.org/). The packages used were rms, nlme, lme4, and mice.

Results
Demographics

We collected data on 4170 patients across 71 sites between 2011 and 2017, with the median (range) number of patients per site being 50 (43–101). In all, 65.1% (n = 2706) of the patients had stones of 0–5 mm (95% CI 63.7–66.6%), 20.6% (n = 855) 5–7 mm (95% CI 19.4–21.8%), and 14.2% (n = 593) >7 mm (95% CI 13.2–15.4%). In all, 8.0% (n = 330) (95% CI 7.2–8.9%) had a negative urine dipstick despite a CT confirmed ureteric stone. In all, 75% (n = 3117) of the patients were discharged with conservative management for their ureteric stone and were included in our primary outcome analysis. The remaining 25% (n = 1045) of the patients were admitted for immediate emergency intervention. Of the 3117 patients discharged with

conservative management, an outcome of either SSP or re-admission for intervention was recorded in 2518/3117 (81%). The median (IQR) age of this group was 47 (35–57) years, median (IQR) stone size was 4 (3–5) mm (Fig. 1), and the median (IQR) WBC was 10.4 (8.1–12.8) × 10^9/L. In all, 60% received a NSAID analgesic and 38% received MET, which in all cases was tamsulosin. The overall SSP rate was 74% (1874/2518) and sepsis after discharge with conservative management was reported in 0.6% (16/2518) (Table 1).

Descriptive and univariate analyses

WBC, neutrophils and CRP

Both WBC (OR 1.03, 95% CI 1.00–1.06; P = 0.04) and neutrophil count (OR 1.03, 95% CI 1.01–1.06; P = 0.02] were found on the univariable analysis to be associated with SSP, whilst CRP was not (OR 1.00, 95% CI 0.99–1.00; P = 0.17]. A WBC value of <4 × 10^9/L had a 92% (12/13) chance of SSP compared to a 73% (1239/1687) chance of SSP for a WBC value of 4–12 × 10^9/L, and 76% (622/817) chance for a WBC value >12 × 10^9/L. For every increase in WBC by 1.0 × 10^9/L, the odds of SSP increase on average by 3% (95% CI 0–6) (P = 0.04) (Table 2). Similarly, as neutrophil count increased by each unit, the odds of SSP increase by 3% (95% CI 1–6) (P = 0.02).

Stone size and stone position

As stone size increased, SSP decreased. SSP for stones <5 mm was 89% (95% CI 87–90) compared to 49% (95% CI 44–53) for stones ≥ 5–7 mm, and 29% (95% CI 23–36) for stones >7 mm (Supplementary information).

As the presenting position of the stone was further down the ureter, the chances of SSP increased. For stones in the upper ureter the SSP rate was 52% (95% CI 48–56), middle ureter was 70% (95% CI 64–76), and lower ureter was 83% (95% CI 81–85) (Table 2 and Supplementary information).

Figure 2 shows the distribution of stones according to size and position, whilst Fig. 3 shows the likelihood of SSP when

Fig. 1 Histogram of stone size.

Table 1 Key patient group characteristics.

Variable	Discharged with conservative management	Discharged with conservative management and outcome available	SSP+	SSP−
N	3117	2518	1874	644
Age, years, median (IQR)	46 (35–57)	47 (35–57)	46 (35–57)	48 (37–59)
Male, %	75	75	75	76
Female, %	25	25	25	24
Past medical history, %	27	28	27	29
WBC, × 10^9/L, median (IQR)	10.4 (8.2–12.8)	10.4 (8.1–12.8)	10.5 (8.3–12.9)	10.1 (7.8–12.5)
Neutrophils, × 10^9/L, median (IQR)	7.8 (5.4–10.2)	7.8 (5.4–10.2)	7.8 (5.5–10.3)	7.5 (4.9–10)
CRP, mg/L, median (IQR)	3.4 [1.0–7.00]	4.0 [1.1–7.1]	3.1 [1–7]	4 [1.3–10]
Creatinine, µmol/L, median (IQR)	91 (77–107)	91 (77–108)	91 (77–107)	92 (76–110)
Stone size, mm, median (IQR)	4 (3–5)	4 (3–5)	4 (3–5)	6 (5–7)
Side, left:right, %	53:47	53:47	52:48	55:45
Upper, %	23	24	17	45
Middle, %	10	10	9	12
Lower, %	67	66	74	43
Hydronephrosis, %	63	63	62	69
Hydroureter, %	56	57	59	51
Perinephric stranding, %	42	42	43	42
NSAIDS, %	61	60	62	59
Opioid, %	55	54	55	55
MET*, %	37	38	40	33
Antibiotics, %	12	12	13	12

SSP+, those that were discharged with conservative management and subsequently achieved SSP; SSP−, those that were discharged with conservative management and did not achieve SSP; MET, tamsulosin.*

Table 2 Univariable analysis presented as ORs with their corresponding 95% CIs and P values. Hospital/institution was treated as a random effect.

Univariable analysis Variable	OR (95% CI)	P
WBC	1.03 (1.00–1.06)	0.04
Age	0.99 (0.99–1.00)	0.02
Sex	0.96 (0.78–1.20)	0.45
Previous stone history	0.90 (0.73–1.11)	0.31
Size 5–7 mm	0.16 (0.13–0.20)	<0.001
Size >7 mm	0.07 (0.05–0.10)	<0.001
Side	1.13 (0.94–1.36)	0.19
Middle ureter	0.46 (0.34–0.63)	<0.001
Upper ureter	0.21 (0.17–0.26)	<0.001
Neutrophils	1.03 (1.01–1.06)	0.02
CRP	1.00 (0.99–1.00)	0.17
Creatinine	1.00 (1.00–1.00)	0.56
Hydronephrosis	0.66 (0.54–0.82)	<0.001
Hydroureter	1.14 (0.91–1.42)	0.26
Perinephric stranding	0.96 (0.76–1.22)	0.75
NSAID oral	1.25 (0.95–1.64)	0.11
NSAID rectal	1.12 (0.87–1.45)	0.38
MET*	1.31 (1.05–1.64)	0.02
Antibiotics	1.06 (0.79–1.43)	0.68
Factor (MET interaction middle ureter)	0.63 (0.40–0.99)	0.05
Factor (MET interaction upper ureter)	0.39 (0.28–0.54)	<0.001
Factor (MET interaction 5–7 mm)	0.31 (0.22–0.44)	<0.001
Factor (MET interaction >7 mm)	0.19 (0.10–0.34)	<0.001

MET, tamsulosin.*

stratified by both stone size and stone position, and highlights the interaction between the two factors. Larger stones >7 mm had a 47% chance of passing if in the lower ureter, but this decreased to only 14% if in the upper ureter. Smaller (<5 mm) stones had an 89% chance of passing in the lower ureter, decreasing to 71% if in the upper ureter.

MET

Data on MET use were available in 2182/2518 patients. A greater proportion of patients using MET had SSP compared to those that did not, at 78% (95% CI 75–81) and 72% (95% CI 70–75), respectively. The odds of SSP in those who took MET was 31% greater than in those who did not take MET (*P* = 0.02) (Table 2). Of note, those who took MET had a greater proportion of lower ureteric stones (68% vs 65%) and fewer upper ureteric stones (21% vs 25%) compared to those who did not (Appendix S2).

Hydronephrosis

Patients who had hydronephrosis reported on their initial CT scans had lower SSP compared to those that did not (62% vs 69%). The odds of SSP in those who had hydronephrosis were 34% less than the odds of SSP in those who did not (*P* < 0.001; Table 2).

Creatinine, hydroureter, perinephric stranding, NSAID use, and antibiotic use

Creatinine, presence of hydroureter, presence of perinephric stranding, NSAID use at presentation, and antibiotic use at presentation did not appear to be associated with SSP on univariable analysis (Table 2).

Multivariate logistic regression

Although WBC was initially seen to be associated with SSP on univariable analysis this was not found to be the case on

Fig. 2 Histogram showing the distribution of stones stratified by stone size (mm) and position.


Fig. 3 SSP (%) as stratified for stone size and position.

multivariable analysis (Table 3). The adjusted OR for WBC was 0.97 (95% CI 0.91–1.04; *P* = 0.39). After adjustment, stone size still predicted SSP. The adjusted odds of SSP for 5–7 mm stones was 82% less than that of 0–5 mm stones,

and the adjusted odds of SSP for stones >7 mm was 92% less than that of 0–5 mm stones. Stone position also predicted SSP after adjustment. The adjusted odds of SSP for mid-ureteric stones was 38% less than that of lower ureteric

Table 3 Multivariable model with interactions terms included.

Multivariable model with interactions terms included		
Factor	OR (95% CI)	P
WBC × 10^9/L	0.97 (0.91–1.04)	0.39
Age	1.00 (0.99–1.00)	0.34
Sex	0.82 (0.62–1.08)	0.15
Size 5–7 mm	0.18 (0.12–0.25)	<0.001
Size >7 mm	0.08 (0.04–0.14)	<0.001
MET	1.11 (0.76–1.61)	0.6
Middle ureter	0.62 (0.37–1.04)	0.07
Upper ureter	0.25 (0.18–0.35)	<0.001
Neutrophils ×10^9/L	1.06 (0.99–1.13)	0.11
Hydronephrosis	0.94 (0.72–1.23)	0.65
Size 5–7 mm*MET	1.29 (0.75–2.23)	0.36
Size >7 mm*MET	2.20 (0.92–5.27)	0.08
Middle ureter*MET	0.83 (0.39–1.78)	0.64
Upper ureter*MET	1.15 (0.67–1.95)	0.61

WBC, White blood cell count; CRP, C-reactive protein; MET, medical expulsive therapy (tamsulosin).

stones ($P < 0.07$) and the odds of SSP for upper ureteric stones was 75% less than that of lower ureteric stones ($P < 0.001$).

After adjustment, MET use (OR 1.11, 95% CI 0.76–1.61: $P < 0.6$) and the presence of hydronephrosis (OR 0.94, 95% CI 0.72–1.23; $P < 0.65$) no longer predicted SSP. For stones >7 mm, the use of MET was associated with greater SSP (OR 2.20, 95% CI 0.92–5.27; $P = 0.08$), although the 95% CIs were wide and included no effect.

Missing data and multiple imputation

Data were missing in 576 cases (23%) for the final multivariable model. As a sensitivity analysis, all the above analyses were repeated with multiple imputation to account for these missing data and only minor changes were seen in the presented ORs. The interpretation of the study findings did not change after imputation (Appendix S3).

Patients not responding to routine care follow-up invitation

In all, 20% of patients did not respond to follow-up invitation by the clinical care team after being discharged with conservative management. These patients had similar demographics to the SSP cohort (Appendix S2). The median (IQR) stone size was 4 (3–5) mm in both groups, with the majority of stones located in the lower ureter (70%).

Discussion

In contrast to previous literature, in the present large multicentre cohort study, we have shown that there was no association between WBC, neutrophil count or CRP on admission and the likelihood of subsequent SSP in patients presenting with acute ureteric colic, who were initially discharged with conservative management. The overall SSP rate was 74% and only 0.6% of those discharged on initial conservative management developed an episode of sepsis, confirming that it is safe to conservatively manage patients with obstructing ureteric stones, providing that they receive close follow-up with urological assessment and/or imaging tests. In addition, stone size and stone position were strong predictors of SSP, and our dataset has confirmed the rate of SSP stratified for stone size and position in a contemporary cohort of patients, where stone size was calculated from a CT scan rather than X-rays or IVU, as was the case in many previously published series. These data can allow clinicians to better counsel their patients on the likelihood of SSP, which should help inform management decisions in acute ureteric colic. As these data are derived from a large multicentre sample of patients, and adjust for key confounding variables, we anticipate that it will be a useful reference standard for the management of ureteric colic.

Our present data have similar overall SSP rates as recent RCTs in this field, validating our findings. The overall SSP rate was 80–81% in SUSPEND [7], 79–86% in the Ye et al. [6] study, and 82–87% in the Furyk et al. [24] study. Whilst previous studies did show an association between inflammatory markers and SSP in one direction or the other, after adjustment for key confounding variables, the MIMIC study did not find an association between WBC, neutrophils or CRP and SSP [11–14]. Although our univariable analysis showed that hydronephrosis and MET were associated with SSP, after adjustment, we found no such associations, which highlights the importance of adjusting for confounding variables.

With regards to MET use, there is much debate in the medical community at this time on its role in acute ureteric colic, with a both a meta-analysis and recent RCTs giving conflicting results [5–7,24]. Previous studies have suggested that in stones of a particular size or location there may be a role for MET, although many of these RCTs have not had adequate power to investigate associations in specific subgroups. Although we found no overall evidence in our dataset to support the role of MET in SSP, we acknowledge that there is some uncertainty about its role in the subgroup of stones >7 mm. Unlike the carefully controlled environment of RCTs, our present data are likely to be more generalisable to clinical practice, where patients acceptability of treatment and local follow-up protocols can differ substantially to those set out within a trial schema, and thus should be used to complement the findings from the interventional studies [25,26].

The current European Association of Urology (EAU) [27] and AUA [10] guidelines do not discuss the role of predictors for SSP beyond stone size. Their guidelines are primarily based on older studies or those with a small sample size,

which may not be readily generalisable to current day practice [9,25]. Data on time to stone passage are based on a 75-patient dataset from 1999, whereas the rates of SSP stratified for stone size are based on a paper from 1993, which pre-dates modern treatments and the quoted figures for SSP differ substantially from current practice, with SSP for stones <4 mm of 38% and SSP for stones >6 mm of 1.2% [9,25]. Further, although the guidelines do differentiate SSP rates in 'small' and 'large' stones, they do not discuss the differences in SSP rates for increases in stone size by every millimetre. The AUA guidelines also specify that evidence for conservative management for mid- and upper ureteric stones is lacking, which is addressed in the present study.

The key strengths of the present study include its multicentre nature, large sample size, and pragmatic nature. The large sample size allowed adequate power to investigate the association of several important patient factors whilst adjusting for key confounders, which was lacking from previous studies. As can be seen from the differences between the univariate and multivariate analysis, these confounding factors were important to account for. Despite being a large multicentre study, due to the robust central independent quality control, missing data for the key variables of interest was infrequent, highlighted by the sensitivity analysis with multiple imputation, which showed no substantial differences. A pragmatic study design was chosen in order to ensure that the results were generalisable to clinical practice.

Nevertheless, there are several limitations to the present study. First, the data were observational in nature, although interventional studies to answer the question of interest may not be feasible. Randomised trials in acute ureteric colic are often underpowered to investigate associations of a number of key variables simultaneously [7,24,26]. We accept that there is the possibility of unmeasured confounding being present that could have influenced the associations seen. Second, the present study was retrospective in nature, although we do not feel this limited the validity of the conclusions. We initially carried out a pilot phase of the study [20] and tested whether retrospective data collection would be suitable; the pilot phase confirmed that retrospective data collection provided accurate and reliable data, and had the benefits of allowing significant follow-up data to be obtained for a large sample of patients in a resource-efficient manner [20]. Third, we also accept that there are alternative valid definitions of SSP. We used a pragmatic definition as utilised in previous landmark studies in acute ureteric colic whereby 'absence of the need for intervention' encompasses both an imaging and clinical judgement-based method for determining SSP. This is an outcome that is of importance to patients with ureteric colic and is thus a valid choice [7]. However, it is entirely possible that such a definition could result in a higher proportion of patients being declared stone free, but it is in accordance with current clinical practice. Exposing patients to excessive radiation from repeated imaging

tests is not in keeping with clinical practice and carries the risk of harm to patients [28]. Fourth, 25% of patients were admitted for immediate intervention and are not included in the present analyses, which could be a potential confounder. As the decision to intervene at initial admission is often multifactorial based on local clinician preference and local policies, including it in our analyses would in itself have led to bias. Thus, the present data are best applied to those patients who are deemed suitable for and have been discharged with conservative management rather than all patients presenting with acute ureteric colic. Finally, a proportion of patients had been lost to follow-up after initial presentation with ureteric colic. Although this was the case, loss to follow-up was minimised as a result of the robust routine clinical follow-up arranged for these patients, who typically had outpatient clinic follow-up or telephone follow-up. When we compared the demographics of this group to the whole cohort we found that they were similar to patients who spontaneously passed their stone. This highlights the need for more robust follow-up pathways for patients discharged with ureteric colic. Further, the results of the present study were consistent when carrying out multiple imputation to account for missing data as a sensitivity analysis.

Conclusions

In patients with acute ureteric colic who are discharged with initial conservative management neither WBC, neutrophil count, nor CRP was associated with SSP, and thus should not be used to help influence decisions on the likelihood that the patient will require future intervention. We also found no benefit from the use of MET in aiding SSP in our present cohort of patients. Stone size and position are the most important determinants of the need for active stone treatment. Our present findings represent the most comprehensive SSP rates for each millimetre increase in stone size from a large contemporary cohort. We anticipate that these data will aid clinicians in managing patients with acute ureteric colic and help guide management decisions and the need for intervention.

Acknowledgements

Conflicts of interest

References

1 Strohmaier WL. [Socioeconomic aspects of urinary calculi and metaphylaxis of urinary calculi] [Article in German]. *Urologe A* 2000; 39: 166–70

2 Hesse A, Brandle E, Wilbert D, Kohrmann KU, Alken P. Study on the prevalence and incidence of urolithiasis in Germany comparing the years 1979 vs. 2000. *Eur Urol* 2003; 44: 709–13

3 Trinchieri A. Epidemiology of urolithiasis: an update. *Clin Cases Miner Bone Metab* 2008; 5: 101–6

4 Romero V, Akpinar H, Assimos DG. Kidney stones: a global picture of prevalence, incidence, and associated risk factors. *Rev Urol* 2010; 12: e86–96

5 Hollingsworth JM, Canales BK, Rogers MA et al. Alpha blockers for treatment of ureteric stones: systematic review and meta-analysis. *BMJ* 2016; 355: i6112

6 Ye Z, Zeng G, Yang H et al. Efficacy and safety of tamsulosin in medical expulsive therapy for distal ureteral stones with renal colic: a multicenter, randomized, double-blind, placebo-controlled trial. *Eur Urol* 2018; 73: 385–91

7 Pickard R, Starr K, MacLennan G et al. Medical expulsive therapy in adults with ureteric colic: a multicentre, randomised, placebo-controlled trial. *Lancet* 2015; 386: 341–9

8 Darrad M, Sibartie T, Inglis J, Rukin N. Is acute ureteroscopy for painful ureteric colic cost effective and beneficial for patients? A cost-analysis. *J Clin Urol* 2017; 10: 17–21

9 Miller OF, Kane CJ. Time to stone passage for observed ureteral calculi: a guide for patient education. *J Urol* 1999;162:688–91

10 Assimos D, Krambeck A, Miller NL et al. Surgical management of stones: American urological association/Endourological society guideline, PART II. *J Urol* 2016; 196: 1161–9

11 Sfoungaristos S, Kavouras A, Katafigiotis I, Perimenis P. Role of white blood cell and neutrophil counts in predicting spontaneous stone passage in patients with renal colic. *BJU Int* 2012; 110: E339–45

12 Park CH, Ha JY, Park CH, Kim CI, Kim KS, Kim BH. Relationship between spontaneous passage rates of ureteral stones less than 8 mm and serum C-reactive protein levels and neutrophil percentages. *Korean J Urol* 2013; 54: 615–18

13 Aldaqadossi HA. Stone expulsion rate of small distal ureteric calculi could be predicted with plasma C-reactive protein. *Urolithiasis* 2013; 41: 235–9

14 Angulo JC, Gaspar MJ, Rodriguez N, Garcia-Tello A, Torres G, Nunez C. The value of C-reactive protein determination in patients with renal colic to decide urgent urinary diversion. *Urology* 2010; 76: 301–6

15 Nuss GR, Rackley JD, Assimos DG. Adjunctive therapy to promote stone passage. *Rev Urol* 2005; 7: 67–74

16 Yamaguchi K, Minei S, Yamazaki T, Kaya H, Okada K. Characterization of ureteral lesions associated with impacted stones. *Int J Urol* 1999; 6: 281–5

17 Kasivisvanathan V, Ahmed H, Cashman S et al. The British Urology Researchers in Surgical Training (BURST) Research Collaborative: an alternative research model for carrying out large scale multi-centre urological studies. *BJU Int* 2018; 121: 6–9

18 Kasivisvanathan V, Kutikov A, Manning TG et al. Safeguarding the future of urological research and delivery of clinical excellence by harnessing the power of youth to spearhead urological research. *Eur Urol* 2018; 73: 645–7

19 von Elm E, Altman DG, Egger M et al. Strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. *BMJ* 2007; 335: 806–8

20 Shah TT, O'Keeffe AG, Gao C et al. A multi-centre cohort study evaluating the role of inflammatory markers in patients presenting with acute ureteric colic (MIMIC). *Int J Surg Protoc* 2017; 6: 1–4

21 McClinton S, Starr K, Thomas R et al. Use of drug therapy in the management of symptomatic ureteric stones in hospitalized adults (SUSPEND), a multicentre, placebo-controlled, randomized trial of a calcium-channel blocker (nifedipine) and an alpha-blocker (tamsulosin): study protocol for a randomized controlled trial. *Trials* 2014; 15: 238 https://doi.org/10.1186/1745-6215-15-238

22 Peduzzi P, Concato J, Kemper E, Holford TR, Feinstein AR. A simulation study of the number of events per variable in logistic regression analysis. *J Clin Epidemiol* 1996; 49: 1373–9

23 Wynants L, Bouwmeester W, Moons KG et al. A simulation study of sample size demonstrated the importance of the number of events per variable to develop prediction models in clustered data. *J Clin Epidemiol* 2015; 68: 1406–14

24 Furyk JS, Chu K, Banks C et al. Distal ureteric stones and tamsulosin: a double-blind, placebo-controlled, randomized, multicenter trial. *Ann Emerg Med* 2016; 67: 86–95.e2

25 Hubner WA, Irby P, Stoller ML. Natural history and current concepts for the treatment of small ureteral calculi. *Eur Urol* 1993; 24: 172–6

26 Meltzer AC, Burrows PK, Wolfson AB et al. Effect of tamsulosin on passage of symptomatic ureteral stones: a randomized clinical trial. *JAMA Intern Med* 2018; 178: 1051–7

27 Turk C, Petrik A, Sarica K et al. EAU guidelines on diagnosis and conservative management of urolithiasis. *Eur Urol* 2016; 69: 468–74

28 Brenner DJ, Hall EJ. Computed tomography–an increasing source of radiation exposure. *N Engl J Med* 2007; 357: 2277–84

Appendix 1

PubMed Indexed Collaborators (BURST Collaborative MIMIC Study Group)

Abboudi H, Abdelmoteleb H , Abu Yousif M, Acher P, Adams R, Ager M, Ahmed I, Ajayi L, Akintimehin A, Akman J, Al Hayek S, Al-Dhahir W, Al-Qassim Z, Al-Shakhshir S, Alberto M, Ali Abdaal C, Arya M, Assaf N, Ayres B, Badgery H, Bateman K, Bdesha A, Bedi N, Begum R, Belal M, Biyani CS, Bolton D, Bultitude M, Burge F, Bycroft J, Cameron F, Campbell A, Cannon A, Carrie A, Chappell B, Chin AOL, Chow K, Christidis D, Clements J, Coode-Bate J, Cronbach P, Curry D, Dasgupta R, Demirel S, Derbyshire L, Din W, Docherty E, Edison E, Eldred-Evans D, Ellis G, Evans S, Foley R, Frymann R, Gallagher M, Gowardhan B, Graham J, Graham S, Gray S, Grice P, Gupta S, Hamad S, Hann G, Harris A, Hatem E, Hawary A, Hayat Z, Hayne D, Hegazy M, Henderson J, Hendry J, Ho C, Hughes-Hallet A, Hussain

A, Hussain Z, Ibrahim H, Irving S, Ivin N, Jaffer A, Jalil R, Kashora F, Kavia R, Kerr L, Khadouri S, Khan A, Khan M, Khan S, Koschel S, Kozan AA, Kum F, Kynaston H, Laird A, Lavan L, Lawrentschuk N, Lee JCM, Lee S, Liew M, Mackenzie K, Malki M, Manson-Bahr D, Mason H, Matanhelia M, Maw J, Mbuvi J, Mc Cauley N, McGrath S, Mc Kay AC, Mcilhenny C, Miakhil I, Miller M, Mirza AB, Morrison-Jones V, Morrow J, Mosey R, Murtagh K, Natarajan M, Nehikhare Y, Ness D, Ng A, Ngweso S, Nkwam N, Nyandoro M, Nzenza T, O'Brien J, O'Rourke J, O'Brien J, Olaniyi P, Olivier J, Osman B, Oyekan A, Pang K, Pankhania R, Parwaiz I, Parys B, Patterson J, Pearce I, Phipps S, Premakumar Y, Probert JL, Quinlan D, Ratan H, Reid K, Rezacova M, Rezvani S, Rodger F, Rogers A, Ross D, Rowbotham C, Rujancich P, Ruljancich P, Sadien I, Sakthivel A, Saleemi A, Samsudin A, Sandhu S, Seaward L, Sharma A, Sharma S, Shergill I, Shetty A, Shingles C, Simmons L, Simpson R, Simson N, Singh H, Smith D, Sriprasad S, Stammeijer R, Steen C, Stewart H, Stonier T, Suraparaj L, Swallow D, Symes A, Symes R, Tailor K, Tait C, Tam JP, Tay J, Tay LJ, Tregunna R, Tudor E, Udovicich C, Umez-Eronini N, Wang L, Ward A, Weeratunga G, Withington J, Wong C, Wozniak S, Yassaie O, Young M.

Correspondence: Taimur T. Shah, British Urology Researchers in Surgical Training (BURST), London, UK.

e-mail: Taimur.shah@ucl.ac.uk

Abbreviations: BURST, British Urology Researchers in Surgical Training; CRP, C-reactive protein; MET, medical expulsive therapy; MIMIC, Multi-centre cohort study evaluating the role of Inflammatory Markers In patients presenting with acute ureteric Colic (study); OR, odds ratio; RCT, randomised control trial; (S)SP, (spontaneous) stone passage; STROBE, the STrengthening the Reporting of OBservational studies in Epidemiology; SUSPEND, Spontaneous Urinary Stone Passage Enabled by Drugs; WBC, white blood cell count.

Supporting Information

Additional Supporting Information may be found in the online version of this article:

Appendix S1. STROBE checklist.
Appendix S2. Supplementary figures.
Figure S1. SSP (%) as stratified for stone size (mm).
Figure S2. SSP (%) as stratified for stone position.
Appendix S3 Patient characteristics for additional patient groups.
Appendix S4. Imputation tables.
Appendix S5. Full list of all authors and their sites.